IL6 and COVID-19: Approximately 20% of patients infected with SARS-CoV-2 (COVID-19) develop potentially life-threatening pathologies involving acute inflammation, cytokine storm, septic shock complications, coagulation dysfunction, metabolic acidosis, hypoxia, and multiple organ failure.1 Consistent blood markers in afflicted patients are normal to low white cell counts and elevated interleukin-6 (IL-6) levels which, among its many activities, signal the liver to increase synthesis and secretion of CRP.2–5